to page content
to site navigation
The Resource Center has all the info you'll need From content to user feedback, the resource center has the information you need for every level of the entrepreneurial process.
Hatteras Venture Partners, a venture capital firm, will invest $20 million to $30 million in helping companies through first-in-man and preclinical studies. The firm expects to invest in 10 to 15 companies in the healthcare business.
Innovations receiving funding at North Carolina State University include two projects with healthcare applications: work on a new Salmonella vaccine and wound-healing bandages.
At-the-market offerings are used for investing in other industries, but they are just starting to pick up in life science investing. Read more on what the healthcare business should know about ATM offerings.
Regenerative medicine has come a long way in recent years, leading some venture capitalists to consider investing in it. The roadblock to investing in this field is not a lack of funds, but rather a lack of a clear explanation of regenerative medicine's commercial applications, says one former venture capitalist.
Life science startups looking for funding should keep foundations in mind as a potential source. Read more for tips on getting funding from foundations.
Nanotechnology startups are competing for investment dollars, but those who have a strong management team and can meet a market need will stand out. Read more tips on getting nanotech investments.
Venture capital investments are in high demand, but some personalized medicine companies succeed in securing dollars. Read more for tips on what venture capitalists want to see in a personalized medicine company before investing in it.
Investing in seed and startup companies is extremely risky: Angel investors typically realize about 85 percent of their total portfolio returns from 15 percent of their portfolio companies. Consequently, angels look only for companies that can grow rapidly. Entrepreneurs who pursue less aggressive growth are unlikely to attract angel investors.
An important voice in the angel investing world, Luis Villalobos has contributed a practical new term--"valuation divergence"--that focuses on a little understood fact of angel investing: Returns on investments in a company do not increase in direct proportion to the company's market valuation. Entrepreneurs and investors alike will benefit from a better understanding of this concept.
This exceptional article offers insightful explanation and key details of how angel investors determine valuations, why entrepreneurs and investors often have different perspectives for angel returns, and what steps angels and entrepreneurs can take to quickly find common ground on this critical topic.
Want to get connected? Sign up to receive regular news, polls and updates from The Kauffman Foundation.